Brachytherapy · 2025
Quantifying geometric and dosimetric advantage from the use of rectal spacing in HDR prostate brachytherapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Beaudry Joel, Wang Tonghe, Aramburu Núñez David, Kollmeier Marisa, Gorovets Daniel, Enger Shirin A, Damato Antonio L
Аннотация
INTRODUCTION: Rectal spacers are used during prostate external beam radiation therapy to increase rectal-prostate separation, thereby reducing rectal dose and toxicity. However, their role in high-dose-rate (HDR) brachytherapy remains less understood. This paper presents (i) a cohort study evaluating the dosimetric impact of rectal spacers in HDR prostate brachytherapy and (ii) a simulation study assessing how rectal-prostate separation affects dosimetry.
METHODS: We retrospectively analyzed 157 patients treated with 15 Gy HDR prostate boost brachytherapy. Patients were divided into preimplant spacer (n = 49) and nonspacer (n = 108) cohorts. Prostate and rectal dose-volume histogram (DVH) metrics were compared, and rectal-prostate separation was measured on intraoperative transrectal ultrasound. A custom linear programming optimizer simulated plans with separations of 0.5-12 mm in 30 nonspacer cases to evaluate resulting dose metrics.
RESULTS: Mean (± standard deviation) rectal-prostate separation was 7.8 ± 1.4 mm with spacer versus 4.0 ± 1.4 mm without spacer. Rectal dose was significantly reduced with spacer (mean D2cc 7.4 ± 1.0 Gy vs. 9.2 ± 1.0 Gy; p < 0.001), while prostate coverage remained similar (mean D90 16.4 ± 0.3 Gy vs. 16.3 ± 0.3 Gy; p = 0.071). Simulations showed that separations > 3 mm consistently achieved prostate D90 > 16 Gy and V100 > 95%, and separations > 4 mm produced a marked reduction in rectal dose.
CONCLUSION: Rectal spacers significantly reduce rectal dose in HDR prostate brachytherapy. Patients with rectal-prostate separations of at least 4 mm are most likely to benefit.
METHODS: We retrospectively analyzed 157 patients treated with 15 Gy HDR prostate boost brachytherapy. Patients were divided into preimplant spacer (n = 49) and nonspacer (n = 108) cohorts. Prostate and rectal dose-volume histogram (DVH) metrics were compared, and rectal-prostate separation was measured on intraoperative transrectal ultrasound. A custom linear programming optimizer simulated plans with separations of 0.5-12 mm in 30 nonspacer cases to evaluate resulting dose metrics.
RESULTS: Mean (± standard deviation) rectal-prostate separation was 7.8 ± 1.4 mm with spacer versus 4.0 ± 1.4 mm without spacer. Rectal dose was significantly reduced with spacer (mean D2cc 7.4 ± 1.0 Gy vs. 9.2 ± 1.0 Gy; p < 0.001), while prostate coverage remained similar (mean D90 16.4 ± 0.3 Gy vs. 16.3 ± 0.3 Gy; p = 0.071). Simulations showed that separations > 3 mm consistently achieved prostate D90 > 16 Gy and V100 > 95%, and separations > 4 mm produced a marked reduction in rectal dose.
CONCLUSION: Rectal spacers significantly reduce rectal dose in HDR prostate brachytherapy. Patients with rectal-prostate separations of at least 4 mm are most likely to benefit.